Physician profile
Asimul Ansari
NPI 1376528919
$15,065.08
in general payments reported to CMS, 2019-2025
45 companies · $4,089 in 2025
The $4,089 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $1,226 · 2021: $1,465 · 2022: $2,761 · 2023: $2,616 · 2024: $1,397 · 2025: $4,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,968 · Travel and Lodging: $2,113 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,968.36 |
| Travel and Lodging | $2,112.59 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,468.20 | 2021-2025 | Mitraclip, Triclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $1,464.60 | 2019-2025 | |
| Amgen INC. | $1,372.01 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $862.59 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $750.48 | 2019-2025 | Jardiance |
| Aop Health US, LLC | $713.59 | 2025 | Rapiblyk |
| Heartflow, INC. | $529.22 | 2020-2025 | |
| Edwards Lifesciences Corporation | $491.11 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $470.98 | 2019-2024 | Xarelto |
| Pfizer INC. | $426.74 | 2019-2025 | |
| Amarin Pharma, INC. | $377.58 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $345.32 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $343.93 | 2019-2024 | Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $319.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $263.64 | 2019-2025 | Camzyos, Eliquis |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asimul Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.